European Journal of Cancer最新文献

{"title":"Corrigendum to “Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): Results from a population-based study” [Eur. J. Cancer 2025 Aug 26;226:115535. PMID: 40743655]","authors":"Annalisa Trama , Silvia Rossi , Damien Bennet , Charles Stiller , Keiu Paapsi , Xavier Troussard , Fabiola Giudici , Henrike E. Karim-Kos , Francesco Cerza , Jan Trallero , Rosalia Ragusa , Marcel Blum , Alexandra Mayer-da-Silva , Frederik Peters , Fabio Didonè , Laura Botta , EUROCARE-6 Working Group","doi":"10.1016/j.ejca.2025.115767","DOIUrl":"10.1016/j.ejca.2025.115767","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":"Article 115767"},"PeriodicalIF":7.1,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Genomic landscape and clinical impact of homologous recombination repair gene mutation in small bowel adenocarcinoma” [Eur J Cancer 220 (2025) 115401]","authors":"Toshiki Ozato , Yoshiyasu Kono , Shigeru Horiguchi , Koichiro Tsutsumi , Hideki Yamamoto , Akira Hirasawa , Daisuke Ennishi , Shuta Tomida , Shinichi Toyooka , Motoyuki Otsuka","doi":"10.1016/j.ejca.2025.115769","DOIUrl":"10.1016/j.ejca.2025.115769","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":"Article 115769"},"PeriodicalIF":7.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival of European adolescents and young adults diagnosed with central nervous system tumours and comparison with younger and older age groups: EUROCARE-6 results.","authors":"Martin McCabe, Silvia Rossi, Francesco Cerza, Maura Massimino, Francesca Gianno, Ben D Spycher, Rafael Marcos-Gragera, Damien Bennett, Paolo Lasalvia, Fabio Didonè, Noura Jeghalef El Karoui, Rosalia Ragusa, Alexandra Mayer-da-Silva, Seyed Mohsen Mousavi, Annalisa Trama","doi":"10.1016/j.ejca.2025.115661","DOIUrl":"10.1016/j.ejca.2025.115661","url":null,"abstract":"<p><strong>Background: </strong>Data on the incidence and survival of central nervous system (CNS) tumour entities in adolescents and young adults (15-39 years at cancer diagnosis [AYA]) are scarce. Our objective is to provide incidence, survival and survival trends of CNS tumours in European AYAs and compare with older and younger patients with the same tumours.</p><p><strong>Methods: </strong>We used the EUROCARE-6 database, calculating incidence rates (IR) per 1000,000 individuals/year in the European population (years of diagnosis: 2006-2013), 1-,2-,3-,4- and 5-year relative survival (RS), 5-year RS conditional to surviving the first year after diagnosis, for the follow-up period 2010-2014 (cases diagnosed in 2006-2013) and changes in survival in the years 2000-2013.</p><p><strong>Results: </strong>The IR for CNS tumours was around 20 per 1000,000 in AYAs and children and increased with increasing age. In AYAs, adults (40-69 years), and elderly (70 + years), CNS tumours other than gliomas were very rare. AYAs had better survival than children for gliomas, ependymomas and medulloblastoma and better survival than adults and elderly for all tumours examined. There was a slight improvement in survival of CNS tumours across age groups in Europe throughout 2000-2013.</p><p><strong>Conclusions: </strong>Differences in survival between children and AYAs may be due to differences in biology and treatment. The improvement in survival may be due to advances in neuroimaging and neurosurgical techniques, centralization of neurosurgical and neurooncology expertise, and multidisciplinary management. Our findings are relevant for informing patients and clinicians about survival in AYA CNS tumours that are rarely included in clinical trials.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"227 ","pages":"115661"},"PeriodicalIF":7.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144811916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.","authors":"Laura L Michel, Philipp Ziegler, Philipp Kreis, Andreas D Hartkopf, Markus Wallwiener, Lothar Häberle, Nelson John, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Johannes Ettl, Diana Lüftner, Volkmar Müller, Erik Belleville, Pauline Wimberger, Hans-Martin Enzinger, Hanna Huebner, Sabrina Uhrig, Carolin C Hack, Petra Krabisch, Peter A Fasching, Rachel Wuerstlein, Michael Untch, Nina Ditsch, Alexander Hein, Wolfgang Janni, Florin-Andrei Taran, Michael P Lux, Diethelm Wallwiener, Sara Y Brucker, Tanja N Fehm, Andreas Schneeweiss, Chloë Goossens, Tobias Engler","doi":"10.1016/j.ejca.2025.115689","DOIUrl":"10.1016/j.ejca.2025.115689","url":null,"abstract":"<p><strong>Introduction: </strong>Whereas CDK4/6 inhibitors (CDK4/6i) are the standard first-line therapy for patients with hormone receptor-positive (HRpos), HER2-negative (HER2neg) metastatic breast cancer, guidelines on treatment options after progression on CDK4/6i are more diverse. Chemotherapy is recommended if a patient develops endocrine resistance or experiences a visceral crisis. However, the impact of the choice of chemotherapy remains unknown.</p><p><strong>Methods: </strong>HRpos/HER2neg patients who received first-line CDK4/6i, followed by second-line chemotherapy (N = 215) were selected from the prospective PRAEGNANT registry (NCT02338167). Cox regression analyses were used to evaluate the correlation between the choice of chemotherapy (capecitabine monotherapy, capecitabine + bevacizumab, taxane monotherapy, taxane + bevacizumab, anthracycline, other chemotherapeutics) and progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>Patients who received second-line chemotherapy mostly had high-grade tumors (G2: 62.3 %, G3: 33.3 %), visceral metastases (62.3 %) and developed metastatic disease following a primary breast cancer diagnosis (73.8 %). Capecitabine was the most common regimen (25.1 %), followed by taxane + bevacizumab (17.2 %). When adjusting for other prognostic factors (age, BMI, grading, ECOG, metastasis group and time to metastases), the choice of chemotherapy did not influence PFS (p = 0.16) nor OS (p = 0.47). Adjusted hazard ratios for PFS were lowest in regimens with bevacizumab (capecitabine as reference; capecitabine + bevacizumab: 0.53 (95 %CI: 0.29, 0.97); taxane + bevacizumab: 0.64 (95 %CI 0.35, 1.15)).</p><p><strong>Conclusion: </strong>Although the choice of chemotherapy post-CDK4/6i did not significantly affect PFS or OS, combinations with bevacizumab may have some benefit. Nevertheless, considering side effects may be most important when choosing the type of second-line chemotherapy.</p>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"227 ","pages":"115689"},"PeriodicalIF":7.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis","authors":"Mario Mandalà ,&nbsp;Filippo Ugolini ,&nbsp;Lorenzo Caldirola ,&nbsp;Eliana Rulli ,&nbsp;Antonella Manca ,&nbsp;Maria Cristina Sini ,&nbsp;Sara Simi ,&nbsp;Gianna Baroni ,&nbsp;Silvia Costabile ,&nbsp;Vincenzo De Giorgi ,&nbsp;Antonio Cossu ,&nbsp;Guido Bellezza ,&nbsp;Antonio Guadagno ,&nbsp;Francesco Spagnolo ,&nbsp;Andrea Gianatti ,&nbsp;Paola Ghiorzo ,&nbsp;Giuseppe Palmieri ,&nbsp;Daniela Massi","doi":"10.1016/j.ejca.2025.115755","DOIUrl":"10.1016/j.ejca.2025.115755","url":null,"abstract":"<div><h3>Background</h3><div>The prognostic impact of tumour microenvironment (TME) heterogeneity in primary cutaneous melanomas (CM) and paired distant metastases is unclear. Few studies have explored the impact of genetic features on TME immune cell distribution. This study assessed the prognostic impact of TME heterogeneity and investigated the correlation between genetic features and TME cell composition.</div></div><div><h3>Methods</h3><div>Demographics, treatments and outcome of melanoma patients - with paired samples - from five Italian Melanoma Intergroup (IMI) centers were collected.</div><div>TME immune phenotypes and cell distribution in FFPE whole tumour sections were analyzed using 9 biomarkers (CD3, CD4, CD8, CD20, CD68, CD163, PD-1, PD-L1, FOXP3), classifying samples as desert (D), excluded (E), or inflamed (I). Additionally, genomic pathways were assessed by next-generation sequencing in both primary and paired samples.</div></div><div><h3>Results</h3><div>TME was evaluated in 221 samples from 91 patients.The distribution of immune phenotype (I vs E/D) of CD8 + cells (p &lt; 0.0001), CD163 + cells (p &lt; 0.0001), CD20 + cells (p = 0.0008), CD3 + cells (p &lt; 0.0001), CD4 + cells (p &lt; 0.0001), CD68 + cells (p &lt; 0.0001), PD1 + cells (p = 0.00015) significantly differed between metastatic and primary melanomas.</div><div>In primary tumors, BRAFV600 status did not correlate with immune phenotypes. However, in paired metastases, it was inversely associated with infiltration of CD8 + , CD3 + , CD68 + , and CD20 + cells. Patients in the CD8 + D/E TME group had significantly shorter median survival (21 months) compared to those with at least one inflamed (I) TME sample [(58 months); HR 2.35, 95 % CI 1.28–4.32].</div></div><div><h3>Conclusions</h3><div>Metastatic and primary melanomas show distinct immune phenotypes. Longitudinal TME assessment predicts overall survival.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":"Article 115755"},"PeriodicalIF":7.1,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics and pharmacodynamics of an anti-CSF1 receptor antibody in the intra-articular treatment of tenosynovial giant cell tumor","authors":"Michiel van de Sande ,&nbsp;Kirk Johnson ,&nbsp;Kirsten van Langevelde ,&nbsp;Thomas Scharschmidt ,&nbsp;Laman Alani ,&nbsp;Dorothy Nguyen ,&nbsp;Tiffany Nguyen ,&nbsp;Chinglin Lai ,&nbsp;Hans Gelderblom","doi":"10.1016/j.ejca.2025.115756","DOIUrl":"10.1016/j.ejca.2025.115756","url":null,"abstract":"<div><h3>Aim</h3><div>CSF1R-targeted pharmacotherapy is a viable treatment approach for TGCT but may be associated with pharmacologic side effects when given systemically. As a first study of its kind, intra-articular (IA) administration of an anti-CSF1R antibody (AMB-05X) into the knee of normal monkeys and TGCT patients was characterized.</div></div><div><h3>Methods</h3><div>Following favorable results of 5 mg/kg IA dosing in monkeys, a multi-center, single-arm, Phase 2a trial was undertaken. IA AMB-05X was administered to the affected knee at 150 mg (N = 8) or 90 mg (N = 3) every 2 weeks for 12-weeks. Safety and tolerability, and efficacy (tumor response assessed on MRI and patient reported outcomes (PROs)), PK, PD, and anti-drug antibody (ADA) were evaluated.</div></div><div><h3>Results</h3><div>IA injection to monkeys was well-tolerated and AMB-05X knee synovial fluid levels were greater than that in serum with a similar half-life. In the clinical trial, most common low-grade treatment-emergent adverse events (TEAEs) were edema (55 %), fatigue (46 %), arthralgia (36 %), rash (36 %) and pruritus or hypertension (27 %). These events were lower in the 90 mg cohort compared to the 150 mg cohort. Q2W dosing resulted in accumulation of high synovial vs systemic AMB-05X (PK) and CSF1 (PD) levels. Objective tumor response by RECISTv1.1 was 36 % overall, while Modified RECIST was 45 %. PROs were significantly improved at 10–12 weeks. ADA was 0 %.</div></div><div><h3>Conclusion</h3><div>Favorable PK, PD, efficacy, and safety/tolerability of intra-articular administration of an anti-CSF1R mAb for TGCT was validated. These results support further development of this novel treatment approach.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":"Article 115756"},"PeriodicalIF":7.1,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145046786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: Avelumab plus axitinib in patients with advanced gastrointestinal stromal tumor","authors":"Zhihao Lei","doi":"10.1016/j.ejca.2025.115753","DOIUrl":"10.1016/j.ejca.2025.115753","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":"Article 115753"},"PeriodicalIF":7.1,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era","authors":"A. Alberti ,&nbsp;C. Gurizzan ,&nbsp;C. Resteghini ,&nbsp;A. Trama ,&nbsp;A. Bernasconi ,&nbsp;S. Grisanti ,&nbsp;M. Zamparini ,&nbsp;I. Mohamad ,&nbsp;I. Linares Galiana ,&nbsp;E. Ozyar ,&nbsp;P. Franco ,&nbsp;S. Vecchio ,&nbsp;P. Bonomo ,&nbsp;B. Cirauqui ,&nbsp;M. El-Sherify ,&nbsp;S. Ursino ,&nbsp;A. Argiris ,&nbsp;J. Pan ,&nbsp;C. Wittekindt ,&nbsp;E. D'Angelo ,&nbsp;Paolo Bossi","doi":"10.1016/j.ejca.2025.115749","DOIUrl":"10.1016/j.ejca.2025.115749","url":null,"abstract":"<div><h3>Aim of the study</h3><div>The aim of the study is to describe clinical features, treatment approach and outcomes of recurrent/metastatic (R/M) NPC in non-endemic areas</div></div><div><h3>Materials and methods</h3><div>This observational, retrospective and multicenter study was conducted within 36 referral hospital in non-endemic areas including Europe, Jordan, Kuwait, Turkey and United States of America. All NPC patients diagnosed between 2004 and 2016 and with a minimum 12 months of follow-up were included. Data entry started in January 2018 and closed in December 2023.</div></div><div><h3>Results</h3><div>A total of 454 patients with R/M NPC were included in this analysis. The most frequent histology was non-keratinizing carcinoma (87 %); de novo metastatic patients had an EBV-related disease in 93 % of the cases. Among those with relapsed disease, locoregional recurrence was the most frequent site of recurrence, while bone was the principal site of metastatic dissemination (58 % of cases). Regarding treatment strategies, patients with loco-regional relapse received re-irradiation more frequently than salvage surgery (43 % vs 38 %). Overall, most of the patients with R/M disease received at least one line of systemic therapy. Median PFS was 13 months, while the median OS was 30 months (range 1–180) with a three year-OS rate of 47 %.</div></div><div><h3>Conclusions</h3><div>This study reports the largest available clinical data defining the outcome of non-endemic patients with R/M NPC. In the context of rare cancers, these data represent the benchmark to define new therapeutic strategies and confirms a similar behaviour of NPC between endemic and non-endemic NPC when correlated with EBV status</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"229 ","pages":"Article 115749"},"PeriodicalIF":7.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144989482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4) [European Journal of Cancer 2024 (2024) 114062]”","authors":"Tiuri E. Kroese ,&nbsp;Sebastiaan Bronzwaer ,&nbsp;Peter S.N. van Rossum ,&nbsp;Hanneke W.M. van Laarhoven ,&nbsp;Richard van Hillegersberg","doi":"10.1016/j.ejca.2025.115712","DOIUrl":"10.1016/j.ejca.2025.115712","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"228 ","pages":"Article 115712"},"PeriodicalIF":7.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144926221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study","authors":"Akihiro Tsukaguchi ,&nbsp;Kinnosuke Matsumoto ,&nbsp;Akihiro Tamiya ,&nbsp;Motohiro Tamiya ,&nbsp;Masahide Mori ,&nbsp;Hidekazu Suzuki ,&nbsp;Takayuki Shiroyama ,&nbsp;Akito Miyazaki ,&nbsp;Kiyohide Komuta ,&nbsp;Yasuhiro Mihashi ,&nbsp;Keijiro Yamauchi ,&nbsp;Kensuke Kanaoka ,&nbsp;Tomoki Kuge ,&nbsp;Yuhei Kinehara ,&nbsp;Koji Azuma ,&nbsp;Toshie Niki ,&nbsp;Koki Moritomo ,&nbsp;Yoshito Takeda ,&nbsp;Atsushi Kumanogoh","doi":"10.1016/j.ejca.2025.115748","DOIUrl":"10.1016/j.ejca.2025.115748","url":null,"abstract":"<div><h3>Background</h3><div>Circadian rhythms modulate immunity, and a preclinical study suggests that the timing of the first immune checkpoint inhibitor dose affects antitumor efficacy. However, clinical confirmation is scarce. We aimed to evaluate whether the timing of the first pembrolizumab infusion affects outcomes in unresectable non-small cell lung cancer (NSCLC).</div></div><div><h3>Methods</h3><div>We retrospectively analyzed patients receiving first-line pembrolizumab monotherapy for unresectable NSCLC between 2017 and 2022 at nine Japanese hospitals. Patients were categorized according to the start of first infusion: early (≤ 11:00 AM) or late (&gt; 11:00 AM). A landmark cohort receiving ≥ 4 cycles was balanced on 14 covariates using propensity score matching. Endpoints were overall survival (OS), progression-free survival (PFS) and severe (grade ≥ 3) immune-related adverse events (irAEs). Sensitivity analysis using inverse probability of treatment weighting (IPTW) was performed.</div></div><div><h3>Results</h3><div>Among 450 eligible patients, 290 met the landmark criteria and 206 were matched (103 per group). Median follow-up was 62.5 months (95 % CI, 56.4–67.9). The early group demonstrated significantly longer median OS (43.7 vs. 32.4 months; HR, 0.67; 95 % CI, 0.46–0.97; <em>P</em> = 0.03). Median PFS was not significantly different (13.8 vs. 11.6 months; HR, 0.80; 95 % CI, 0.59–1.10; <em>P</em> = 0.17). Severe irAEs were more frequent with early infusion (26.2 % vs. 13.6 %; <em>P</em> = 0.04). IPTW analysis confirmed the OS advantage with early infusion (HR, 0.65; 95 % CI, 0.45–0.94; <em>P</em> = 0.02).</div></div><div><h3>Conclusion</h3><div>Early morning administration of first pembrolizumab infusion was associated with improved OS and more frequent severe irAEs. Initial dose timing may be a simple, feasible variable warranting prospective validation.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"228 ","pages":"Article 115748"},"PeriodicalIF":7.1,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144926220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}